Johnson & Johnson Sees 21% Stock Upside on 9.8% Revenue CAGR to $127.7B
JNJ•Excluding a 920-basis-point headwind from the STELARA patent cliff, Johnson & Johnson’s Innovative Medicine segment delivered 7.4% growth, driving companywide double-digit revenue gains. A conservative three-year model projects revenue compounding at 9.8% annually to $127.7B and earnings rising 42%, supporting a potential 21% stock upside.
1. Underlying Growth Performance
Johnson & Johnson’s overall growth was bolstered by 7.4% expansion in its Innovative Medicine segment despite a 920-basis-point drag from the STELARA patent expiration. Excluding that legacy drug impact, the company achieved double-digit revenue gains in the latest quarter, signaling broad-based momentum across its portfolio.
2. Financial Projections and Valuation
A three-year scenario models revenue rising from $96.4B to $127.7B at a 9.8% annual rate and earnings jumping from $21.0B to $29.9B, a 42% increase. Applying a P/E multiple trimmed from 27.3x to 23.2x generates a target share price near $288.05, implying roughly 21% upside versus current valuation.
3. Pipeline Drivers and ICOTYDE Uptake
Management highlights the strongest product pipeline in company history as a key growth lever, with new oral peptide ICOTYDE already prescribed to about 1,500 psoriatic disease patients since launch. Continued portfolio innovation and compound revenue growth underpin the optimistic operational outlook.
